CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Ensartinib

恩沙替尼 杂质对照品Ensartinib Impurities

41 个杂质条目41 impurity entries

本页汇总 恩沙替尼 的 41 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 41 impurity reference standards of Ensartinib. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 恩沙替尼(Ensartinib)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsDevelopment and Validation of a UPLC-MS/MS Method for Simultaneous Quantification of Ensartinib and Its Major Metabolite M465 in Rat Plasma and Application to Pharmacokinetic Studies
    Drug design, development and therapy · 2026 · Jiang S et al.  ·  PMID 42719333  ·  DOI
  2. 分析方法Analytical MethodsLC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib
    Journal of pharmaceutical and biomedical analysis · 2025 · Meertens M et al.  ·  PMID 40743983  ·  DOI
  3. 分析方法Analytical MethodsSpectrofluorometric and spectrophotometric assay of anticancer drug ensartinib using ion-pair complex formation reaction with eosin Y
    Scientific reports · 2026 · Salem H et al.  ·  PMID 42567906  ·  DOI

恩沙替尼 —— 原料药与杂质对照品Ensartinib — drug substance & impurities

共 42 个条目(含原料药本体)42 items incl. the drug substance
Ensartinib structure
原料药 APIAPI
恩沙替尼Ensartinib
Ensartinib
CAS No.1370651-20-9
Chemical FormulaC26H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 1 structure
1
恩沙替尼杂质1Ensartinib Impurity 1
Ensartinib Impurity 1
CAS No.446273-59-2
Chemical FormulaC4H3BrClN3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 2 structure
2
恩沙替尼杂质2Ensartinib Impurity 2
Ensartinib Impurity 2
CAS No.756520-66-8
Chemical FormulaC8H7Cl2FO
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 3 structure
3
恩沙替尼杂质3Ensartinib Impurity 3
Ensartinib Impurity 3
CAS No.1370651-29-8
Chemical FormulaC12H9Cl3FN3O
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 4 structure
4
恩沙替尼杂质4Ensartinib Impurity 4
Ensartinib Impurity 4
CAS No.1370651-32-3
Chemical FormulaC22H25Cl3FN3O5
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 5 structure
5
恩沙替尼杂质5Ensartinib Impurity 5
Ensartinib Impurity 5
CAS No.1370651-34-5
Chemical FormulaC25H30Cl2FN3O7
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 6 structure
6
恩沙替尼杂质6Ensartinib Impurity 6
Ensartinib Impurity 6
CAS No.1370651-36-7
Chemical FormulaC23H26Cl2FN3O7
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 7 structure
7
恩沙替尼杂质7Ensartinib Impurity 7
Ensartinib Impurity 7
CAS No.3024090-98-7
Chemical FormulaC6H14N2
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 8 structure
8
恩沙替尼杂质8Ensartinib Impurity 8
Ensartinib Impurity 8
CAS No.1370650-92-2
Chemical FormulaC26H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 9 structure
9
恩沙替尼杂质9Ensartinib Impurity 9
Ensartinib Impurity 9
CAS No.2819956-02-8
Chemical FormulaC26H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 10 structure
10
恩沙替尼杂质10Ensartinib Impurity 10
Ensartinib Impurity 10
CAS No.2650136-57-3
Chemical FormulaC26H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 11 structure
11
恩沙替尼杂质11Ensartinib Impurity 11
Ensartinib Impurity 11
CAS No.1370651-17-4
Chemical FormulaC26H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 12 structure
12
恩沙替尼杂质12Ensartinib Impurity 12
Ensartinib Impurity 12
CAS No.2650029-77-7
Chemical FormulaC26H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 13 structure
13
恩沙替尼杂质13Ensartinib Impurity 13
Ensartinib Impurity 13
CAS No.1370651-14-1
Chemical FormulaC25H25Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 14 structure
14
恩沙替尼杂质14Ensartinib Impurity 14
Ensartinib Impurity 14
CAS No.2650168-94-6
Chemical FormulaC25H25Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 15 structure
15
恩沙替尼杂质15Ensartinib Impurity 15
Ensartinib Impurity 15
CAS No.2446803-31-0
Chemical FormulaC24H23Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 16 structure
16
恩沙替尼杂质16Ensartinib Impurity 16
Ensartinib Impurity 16
CAS No.1202001-98-6
Chemical FormulaC24H23Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 17 structure
17
恩沙替尼杂质17Ensartinib Impurity 17
Ensartinib Impurity 17
CAS No.1365267-27-1
Chemical FormulaC25H25Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 18 structure
18
恩沙替尼杂质18Ensartinib Impurity 18
Ensartinib Impurity 18
CAS No.1370650-61-5
Chemical FormulaC25H25Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 19 structure
19
恩沙替尼杂质19Ensartinib Impurity 19
Ensartinib Impurity 19
CAS No.1202001-97-5
Chemical FormulaC25H25Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 20 structure
20
恩沙替尼杂质20Ensartinib Impurity 20
Ensartinib Impurity 20
CAS No.1370651-11-8
Chemical FormulaC26H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 21 structure
21
恩沙替尼杂质21Ensartinib Impurity 21
Ensartinib Impurity 21
CAS No.1370650-81-9
Chemical FormulaC26H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 22 structure
22
恩沙替尼杂质22Ensartinib Impurity 22
Ensartinib Impurity 22
CAS No.2650001-62-8
Chemical FormulaC26H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 23 structure
23
恩沙替尼杂质23Ensartinib Impurity 23
Ensartinib Impurity 23
CAS No.2516243-85-7
Chemical FormulaC25H22Cl2FN7O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 24 structure
24
恩沙替尼杂质24Ensartinib Impurity 24
Ensartinib Impurity 24
CAS No.1370650-71-7
Chemical FormulaC26H27Cl2FN6O4
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 25 structure
25
恩沙替尼杂质25Ensartinib Impurity 25
Ensartinib Impurity 25
CAS No.2516243-84-6
Chemical FormulaC24H23Cl2FN6O4
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 26 structure
26
恩沙替尼杂质26Ensartinib Impurity 26
Ensartinib Impurity 26
CAS No.1370650-89-7
Chemical FormulaC29H31Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 27 structure
27
恩沙替尼杂质27Ensartinib Impurity 27
Ensartinib Impurity 27
CAS No.1370650-97-7
Chemical FormulaC25H24Cl2F2N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 28 structure
28
恩沙替尼杂质28Ensartinib Impurity 28
Ensartinib Impurity 28
CAS No.1201916-44-0
Chemical FormulaC24H22Cl2FN5O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 29 structure
29
恩沙替尼杂质29Ensartinib Impurity 29
Ensartinib Impurity 29
CAS No.1370650-66-0
Chemical FormulaC24H22Cl2FN5O4
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 30 structure
30
恩沙替尼杂质30Ensartinib Impurity 30
Ensartinib Impurity 30
CAS No.2516243-83-5
Chemical FormulaC25H23Cl2FN6O4
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 31 structure
31
恩沙替尼杂质31Ensartinib Impurity 31
Ensartinib Impurity 31
CAS No.1370650-85-3
Chemical FormulaC27H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 32 structure
32
恩沙替尼杂质32Ensartinib Impurity 32
Ensartinib Impurity 32
CAS No.1370651-23-2
Chemical FormulaC25H24Cl2FN5O4
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 33 structure
33
恩沙替尼杂质33Ensartinib Impurity 33
Ensartinib Impurity 33
CAS No.1370651-05-0
Chemical FormulaC27H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 34 structure
34
恩沙替尼杂质34Ensartinib Impurity 34
Ensartinib Impurity 34
CAS No.2649840-86-6
Chemical FormulaC27H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 35 structure
35
恩沙替尼杂质35Ensartinib Impurity 35
Ensartinib Impurity 35
CAS No.1370650-76-2
Chemical FormulaC29H31Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 36 structure
36
恩沙替尼杂质36Ensartinib Impurity 36
Ensartinib Impurity 36
CAS No.2516243-86-8
Chemical FormulaC26H24Cl2FN7O4
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 37 structure
37
恩沙替尼杂质37Ensartinib Impurity 37
Ensartinib Impurity 37
CAS No.2516243-82-4
Chemical FormulaC25H27Cl2FN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 38 structure
38
恩沙替尼杂质38Ensartinib Impurity 38
Ensartinib Impurity 38
CAS No.1370651-08-3
Chemical FormulaC24H21Cl2FN6O4
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 39 structure
39
恩沙替尼杂质39Ensartinib Impurity 39
Ensartinib Impurity 39
CAS No.1370650-99-9
Chemical FormulaC30H34Cl2FN7O3
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 44 (N1-NitrosoEnsartinib Impurity 7) structure
44
恩沙替尼杂质44 (N1-亚硝基恩沙替尼杂质7)Ensartinib Impurity 44 (N1-NitrosoEnsartinib Impurity 7)
Ensartinib Impurity 44 (N1-NitrosoEnsartinib Impurity 7)
CAS No.77267-11-9
Chemical FormulaC6H13N3O
Purity>95%询价On request
10mg25mg50mg100mg
Ensartinib Impurity 45 (N2-NitrosoEnsartinib Impurity 7) structure
45
恩沙替尼杂质45 (N2-亚硝基恩沙替尼杂质7)Ensartinib Impurity 45 (N2-NitrosoEnsartinib Impurity 7)
Ensartinib Impurity 45 (N2-NitrosoEnsartinib Impurity 7)
CAS No.69271-56-3
Chemical FormulaC6H12N4O2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

For formulation & analytical R&D

恩沙替尼 杂质谱研究要点Ensartinib — impurity profiling notes

下面这些是拿到 恩沙替尼 的 42 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 42 impurity entries for Ensartinib, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances